Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
September 14, 2024 03:10 ET
|
Acrivon Therapeutics, Inc
Confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) observed in prospectively-selected ACR-368 OncoSignature-positive (BM+) patients with endometrial cancer Achieved statistically...
NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024
September 14, 2024 03:01 ET
|
NuCana plc
BARCELONA, Spain, Sept. 14, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with...
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
September 14, 2024 03:00 ET
|
Immunocore Holdings plc
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Brenetafusp is clinically active as monotherapy and in combination with...
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
September 14, 2024 03:00 ET
|
Sutro Biopharma, Inc.
- 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in a 56% objective response rate in patients with late-stage ovarian...
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
September 14, 2024 02:30 ET
|
iTeos Therapeutics Inc.
- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose- >30% cORR difference...
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
September 14, 2024 02:30 ET
|
IO Biotech
-- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the Head and Neck Cohort -- -- No New Safety Signals...
VALUE LINE, INC. ANNOUNCES FIRST QUARTER EARNINGS
September 13, 2024 17:18 ET
|
Value Line, Inc.
Value Line, Inc. 551 Fifth Avenue New York, NY 10176 New York, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Value Line, Inc., (NASDAQ: VALU) reported financial results for the first fiscal quarter ended...
Upwork Confirms Receipt and Comments on Shareholder Letter
September 13, 2024 17:03 ET
|
Upwork Inc.
SAN FRANCISCO, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Upwork Inc. (Nasdaq: UPWK), the world’s largest work marketplace that connects businesses with independent talent across the globe, today issued the...
Westport Announces At-the-Market Equity Offering Program
September 13, 2024 17:00 ET
|
Westport Fuel Systems Inc.
VANCOUVER, British Columbia, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Westport Fuel Systems Inc. (TSX: WPRT / Nasdaq: WPRT) (“Westport” or “The Company”) announces that it has established an at-the-market...
Galaxy Payroll Group Limited Announces Closing of $7 Million Initial Public Offering
September 13, 2024 16:30 ET
|
Galaxy Payroll Group Limited
Hong Kong, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Galaxy Payroll Group Limited (the “Company” or “GLXG”), a reputable payroll outsourcing service, employment service and consultancy and market research...